Archive for category: Announcements

Anuga is the largest and most important food and beverage exhibition in the world. More than 160,000 trade visitors from 192 countries travel to Cologne to attend the five-day fair.

We woul dlike to inform you that Enterprise Europe Network Hellas in cooperation with Enterprise Greece are organizing a networking event, ANUGA 2023 – Greek Matchmaking event, in the framework of the International Exhibition “ANUGA 2023” and invite potential buyers, active in the food and beverage sector, to participate.

Therefore, If you are planning to visit ANUGA Exhibition in Cologne to establish valuable cross-border contacts and collaborations with key players in the Greek food and beverage industry, you can now register by clicking on the following link: Anuga 2023 Greek Matchmaking event.

Event Details:

• Location: Cologne, Germany (Europasaal Hall 10/11, Stand No 018G)
• Date: 8th-10th October | 10:00 AM to 4:00 PM
• Registration deadline: 7th October 2023

Who can participate?

• International buyers: Importers, distributors, food and beverage wholesalers (including wine and alcoholic beverages), representatives of food chains, supermarkets, procurement agents for hotels and restaurants, specialty food and wine stores, e-commerce buyers, and others.

Cost:

The business meetings at the “ANUGA 2023 – Greek Matchmaking Event” will be free of charge and will take place on-site at the exhibition. However, registration at the ANUGA 2023 fair is mandatory and a prerequisite for participating in the business meetings.

For more information about ANUGA 2023 and registration, click HERE.

Regarding the above issue, we would like to inform you that two new Regulations have been published in the Official Journal of the European Union and they appear below. The following links also include the timetables for the implementation of the Regulations.

1. COMMISION REGULATION (EU) 2023/1545 of 26 July 2023

amending Regulation (EC) No. 1223/2009 of the European Parliament and of the Council as regards labelling of fragrance allergens in cosmetic products.

2. COMMISSION REGULATION (EU) 2023/1490 of 19 July 2023

amending regulation (EC) No. 1223/2009 of the European Parliament and of the Council as regards the use in cosmetic products of certain substances classified as carcinogenic, mutagenic or toxic for reproduction.

From October 12^th and 13^th, the third edition of Innovative therapies days – ITD (www.innovativetherapiesdays.com) will be held in Besançon (25), France.

Innovative Therapies Days is the key symposium that will give a large part to exchanges between experts in their field: ??????????, ??????????, ??? ?????????? ????????. You will find them through an ????????? ???????, ??? ????????, ??? ?????????? ????? and discover their latest scientific progress on CAR-T cells, cell therapies, and cell-derived innovative therapies. While the Bourgogne-Franche-Comté region is the birthplace of microtechnology, it is the combination of those technologies with cell therapies that enabled the RIGHT institute to bring out flagship products like CAR-T cells! With some national partners and international partners and around 600 visitors, ITD brings together ??????????, ??????????, ??? ?????????? ???????? for 2 days of high-level conferences about CAR-T cells, cell therapies, cell-derived innovative therapies and regulation, production, and clinical transfer of innovative therapies.

• CAR-T CELLS, CELL THERAPIES, CELL-DERIVED INNOVATIVE THERAPIES

This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.

Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.

• REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES

This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.

We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America.

As a partner of this event, Enterprise Europe Network offers you an additional 10% discount using the code PREFEE-POLES-CLUSTERS-PARTNERS.

Until July 30th, take advantage of an early bird offer !

Find out more about the program, the partners, and details at www.innovativetherapiesdays.com.

The EU has implemented rules to address IBAN discrimination within Member States with the Single Euro Payments Area Regulation (SEPA Regulation).

According to Article 9 of Regulation (EU) No. 260/2012 (SEPA) the following are defined:

• a payer, who performs a credit transfer to a payee who holds a payment account within the European Union shall not specify in which member state the payment account is to be held, provided that such payment account is reachable in accordance with the rules of a European Union-wide payment scheme.
• a payee, who accepts a transfer or uses a direct debit to collect funds from a payer, who holds a payment account within the European Union shall not specify in which member state this payment account is to be held, provided that the payment account is reachable in accordance with the rules of a European Union-wide payment scheme.

Although the Regulation has been in force since March 2012, citizens and businesses operating across borders are faced with the rejection of their IBAN because it starts with the letters of their country of origin (for example CY, GR, FR, etc.) or the digit length of the IBAN differs from the domestic one (for example, it has less than 34 alphanumeric characters).

To solve this, they are forced to obtain a new bank account in the host member state. That is not always easy. Especially if the company is not established or the citizen does not reside in the member state from/to which the payment is made. For businesses, this can even lead to the closure of their economic activity.

IBAN discrimination occurs in both the private sector and public services. According to information from the EC, most complaints of IBAN discrimination concern telecommunications providers. However, the consequences of discrimination by public authorities can be more severe because there is often no alternative to public service. Businesses may not be able to pay their taxes, get their VAT money back, apply for promotions, or obtain certificates. While citizens may face difficulties, for example, with tax authorities and receiving pensions or reimbursement of healthcare expenses.

The European Commission’s Single Market Enforcement Task Force (SMET) is exploring this issue with a view to taking action to eliminate discrimination.

That is why, to support the efforts of the Task Force, we would like you to inform us whether you have faced similar treatment. That is, if you tried to make credit transfers within the Single Euro Payments Area (SEPA) or direct debits within SEPA to pay bills, purchase products or services online, pay taxes or collect tax refunds, unemployment benefits, or other benefits, and your account was rejected because it is located in an EU country other than the country of the other party. Please note that the information collected will be given anonymously to the Task Force.

The survey will be open until August 16, 2023, and you can participate by completing the form found HERE.